Goes on for another year with the funding of a new research project on Pediatric AML

Goes on for another year with the funding of a new research project on Pediatric AML

In the last two years, Fondazione Ginevra Caltagirone has granted pediatric projects presented by Fondazione Umberto Veronesi, a major contribution to the achievement of important results for the treatment of acute myeloid leukemia of children.

With important results achieved in this field, has also acted with great pleasure for the year 2014/2015 a new loan of 48,000 euros for the continuation of the research project of Dr. Riccardo Masetti.

Over the past two years the research project of Dr. Riccardo Masetti has achieved important results that have, in addition to a wide international visibility, a strong relapse therapy on clinical care of children with AML.

Acute Myeloid Leukemia has a poor prognosis, with a disease-free survival at 5 years after diagnosis by about 50%.

The first cause of treatment failure is relapse of the disease. The return of the underlying disease after a longer or shorter period of complete remission occurs in approximately one third of children treated and is the real reason for determining a prognosis so poor. The prognosis for relapsed patients is significantly worse than the debut.

In the pediatric setting, there are no studies that evaluate these developments and it is in this area that fits the new research project whose aim is to define the clonal evolution of leukemic cell of cases of AML with normal karyotype in pediatric age by Whole-Exome Sequencing.

All this happened thanks to the contribution of Fondazione Ginevra Caltagirone which has incorporates the spirit and objectives of the FUV in support of scientific research, indispensable resource to find new cures and give hope to those who did not have it today.

Most important is therefore continue to support the work of Dr. Masetti to give real hope of healing to all those children who have failed, despite great efforts to defeat the disease.

Defending health means doing research, and also thanks to our support this kind of research can continue to exist. It is a very important choice help non-profit organizations active in the field of scientific research. A choice to be proud of. That's why Fondazione Ginevra Caltagirone will continue for another year to fund research projects in pediatric oncology, where researchers and highly skilled pediatric oncologists are continually looking for new therapies and drugs more effective and less toxic than those available today.